“I spent 20 years trying to do immunotherapy and we weren’t as successful as we wanted to be probably because we didn’t recognize the degree to which the environment within the tumor is so suppressive,” said Dr. Dan Sterman during our latest Meet the Mesothelioma Experts broadcast referring to the inability of the immune system […]
Articles by Meso Foundation
At the end of October of 2017, Dr. H. Richard Alexander, esteemed surgeon specializing in peritoneal mesothelioma, will be moving from his current institution, the University of Maryland, to Rutgers University in New Jersey. His new position as Chief Surgical Officer will combine administrative as well as clinical duties. As such, Dr. Alexander will also […]
In a statement released on Sunday, Bayer announced that Anetumab ravtansine, its antibody-drug conjugate (ADC) tested in mesothelioma, has missed its primary endpoint failing to improve progression-free survival in mesothelioma patients.
“Malignant pleural mesothelioma is a very difficult-to-treat tumor, and we had hoped for a better outcome for patients,” said Robert LaCaze, Executive Vice President and […]
Mesothelioma researcher and Meso Foundation grant recipient Prasad S. Adusumilli, MD, FACS, FCCP, of the Memorial Sloan Kettering Cancer Center (MSKCC) was an author on the review article CAR T-cell therapy for lung cancer and malignant pleural mesothelioma recently published in Translational Research: The Journal of Laboratory and Clinical Medicine.
Dr. Adusumilli is a thoracic surgeon-scientist […]
Joseph R. Testa, PhD, of the Fox Chase Cancer Center has edited a newly published book titled “Asbestos and Mesothelioma” to serve as a resource for researchers and medical professionals in the field. Mary Hesdorffer, NP, Executive Director at the Meso Foundation co-authored one of the book’s chapters.
More information about the book follows:
“Asbestos and Mesothelioma,” […]